CDC's ACIP adult recommendations for Prevnar 13®

The information below represents the CDC’s ACIP recommendations to complete the pneumococcal vaccination sequence for immunocompetent adults aged 65 and older1,2
As stated by the CDC’s ACIP:
  • For adults aged ≥65 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants, the recommended interval between Prevnar 13® followed by Pneumovax® 23 is ≥8 weeks.1
  • The 2 vaccines (Prevnar 13® and Pneumovax® 23) should not be coadministered. If a dose of Pneumovax® 23 is inadvertently given earlier than the recommended interval, the dose need not be repeated.1
Prior receipt of Pneumovax® 23 within 1 year results in diminished immune responses to Prevnar 13® compared to Pneumovax® 23-naive individuals.4
Pneumovax is a registered trademark of Merck & Co., Inc.
ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; IPD=invasive pneumococcal disease.
In accordance with the CDC's ACIP recommendations for adults aged 65 and older, administer both Prevnar 13® and Pneumovax® 23 to help protect against pneumococcal pneumonia and IPD1
The CDC’s ACIP recommends Prevnar 13® in series with Pneumovax® 23 for immunocompromised patients aged 19 and older with the following medical conditions:5
  • Congenital or acquired immunodeficiencies*
  • Human immunodeficiency virus (HIV)
  • Chronic renal failure
  • Nephrotic syndrome
  • Leukemia
  • Lymphoma
  • Hodgkin disease
  • Generalized malignancy
  • Iatrogenic immunosuppression†
  • Solid organ transplant
  • Multiple myeloma
  • Functional or anatomic asplenia (including sickle cell disease/other hemoglobinopathies and congenital or acquired asplenia)
  • Cerebrospinal fluid leaks
  • Cochlear implants
*Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).
†Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy.
  • A second dose of Pneumovax® 23 is recommended (≥8 weeks after a dose of Prevnar 13® and 5 years after the most recent dose of Pneumovax® 23) for persons aged 19-64 years with functional or anatomic asplenia (including sickle cell disease/other hemoglobinopathies and congenital or acquired asplenia) and for persons with immunocompromising conditions5
  • Additionally, those who received Pneumovax® 23 before age 65 for any indication should receive another dose of Pneumovax® 23 at age 65 or later if at least 5 years have elapsed since their previous Pneumovax® 23 dose5
For complete ACIP recommendations published October 12, 2012, visit the CDC Morbidity and Mortality Weekly Report website at www.cdc.gov/mmwr.5
IMPORTANT PRESCRIBING INFORMATION FOR PREVNAR 13®
  • Individuals with altered immunocompetence, including those at higher risk for invasive pneumococcal disease (eg, individuals with congenital or acquired splenic dysfunction, HIV infection, malignancy, hematopoietic stem cell transplant, nephrotic syndrome), may have reduced antibody responses to immunization with Prevnar 13®4
  • Immunogenicity data for Prevnar 13® in adults who are at high risk for pneumococcal disease are limited to individuals with HIV infection or with a hematopoietic stem cell transplant. The effectiveness in these and other high-risk populations is not established4
  • The appropriate use of Prevnar 13® in adults with immunocompromising conditions should be based on a risk/benefit assessment by the practitioner for the individual patient
  • Prior receipt of Pneumovax® 23 within 1 year results in diminished immune responses to Prevnar 13® compared to Pneumovax® 23-naive individuals4
Pneumovax is a registered trademark of Merck & Co., Inc.
ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention.
 
ACIP Votes to Revise the Adult Pneumococcal Guidelines
  • On June 26, 2019, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) voted to revise the adult pneumococcal vaccination guidelines and recommend Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) (PCV13) based on shared clinical decision making for adults 65 years or older who do not have an immunocompromising condition
  • The ACIP recommendations are not final until published in the Morbidity and Mortality Weekly Report (MMWR), as the CDC publication represents the final and official CDC recommendations for immunization of the US population
  • Once the ACIP recommendations have been reviewed and approved by the CDC Director and the US Department of Health and Human Services, they will be published in the MMWR
The ACIP recommendation for Prevnar 13® in immunocompromised adults aged 19 and older has not changed.1
The power of prevention remains in your hands
These revised recommendations reaffirm the importance of your role in adult vaccination. The decision to vaccinate should be made at the individual level between you and your patients.
Reference: 1. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-819.
Manufactured by Wyeth Pharmaceuticals Inc.
Marketed by Pfizer Inc.
PP-PNA-USA-3622
© 2019 Pfizer Inc. All rights reserved. June 2019
Close
Pfizer Home

Clinical Information